New Drug Application Submitted for Treatment of P. aeruginosa

https://bronchiectasisnewstoday.com/2017/07/28/non-cystic-fibrosis-bronchiectasis-candidate-therpay-nda-submitted-for-linhaliq-for-p-aeruginosa-infection/

New Drug Application Submitted for Linhaliq as Treatment of Pseudomonas Aeruginosa Infection in NCFBE Patients

The pharmaceutical company Aradigm has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Linhaliq Continue reading New Drug Application Submitted for Treatment of P. aeruginosa

Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference

Spyryx Biosciences Expands Development Award with Cystic Fibrosis Foundation; Presents Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference
-No dose-limiting adverse effects in 14-day multiple ascending dose study
-The Company to receive up to total of $5 million to support Phase 2 trial

DURHAM, N.C., June 20, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address Continue reading Phase 1 Data for SPX-101 at the European Cystic Fibrosis Conference

First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554

https://cysticfibrosisnewstoday.com/2017/06/08/cystic-fibrosis-patients-in-american-arm-of-phase-2a-trial-begin-receiving-rpl554/?utm_source=Cystic+Fibrosis&utm_campaign=64d2239573-RSS_MONDAY_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b075749015-64d2239573-71418393

Cystic fibrosis patients in the United States have begun receiving the anti-inflammatory and airway-opening agent RPL554 in a Phase 2a clinical Continue reading First Cystic Fibrosis Patients in U.S. Arm of Phase 2a Clinical Trial Receive RPL554

Clinical and Regulatory Progress Across Pipeline Programs for Drug Company

http://www.nasdaq.com/press-release/proteostasis-therapeutics-announces-clinical-and-regulatory-progress-across-pipeline-programs-20170607-00270

Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs

Updates Announced During the 40th European Cystic Fibrosis Society Conference

Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by Continue reading Clinical and Regulatory Progress Across Pipeline Programs for Drug Company

Cystic Fibrosis Foundation to Give $3 Million for Novel CFTR Therapeutic

Arcturus Therapeutics, Inc. (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that it has entered into a research agreement with Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation in which CFFT will pay up to $3 million to advance LUNAR-CF, a novel messenger RNA (mRNA) therapeutic formulated with Arcturus’ LUNAR™ delivery technology.

Continue reading Cystic Fibrosis Foundation to Give $3 Million for Novel CFTR Therapeutic

Clinical trial assessing the potential of novel anti-inflammatory investigational therapy

http://m.marketwired.com/press-release/celtaxsys-announces-full-enrollment-its-landmark-empire-cf-phase-2b-clinical-trial-assessing-2216923.htm

Celtaxsys announces full enrollment of its landmark EMPIRE-CF phase 2b clinical trial assessing the potential of novel anti-inflammatory investigational therapy, oral acebilustat, to preserve lung function in CF patients
Continue reading Clinical trial assessing the potential of novel anti-inflammatory investigational therapy

New Drug to Help with Resistant Fungal Lung Infections

TGV-inhalonix, a New York drug development company behind ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections. Continue reading New Drug to Help with Resistant Fungal Lung Infections

You are invited to attend a free web-cast event SATURDAY, APRIL 22, 2017

RARE LUNG DISEASES PATIENT EDUCATION DAY ON CYSTIC FIBROSIS, CHILDREN’S INTERSTITIAL LUNG DISEASE AND PRIMARY CILIARY DYSKINESIA

REGISTER NOW AT:
https://attendee.gotowebinar.com/register/6993341835513746691

This event is co-sponsored by the American Thoracic Society, the Cystic Fibrosis Foundation, the Children’s Interstitial Lung Disease Foundation and the Primary Continue reading You are invited to attend a free web-cast event SATURDAY, APRIL 22, 2017

News about Concert Pharmaceuticals’ cystic fibrosis drug

http://cen.acs.org/articles/95/web/2017/03/Vertex-buys-Concerts-cystic-fibrosis-drug.htm

Vertex buys Concert’s cystic fibrosis drug
Vertex Pharmaceuticals will pay up to $250 million for Concert Pharmaceuticals’ cystic fibrosis drug CTP-656. Currently in Phase II clinical trials, the drug is a deuterated version of Vertex’s own Continue reading News about Concert Pharmaceuticals’ cystic fibrosis drug

Phase 2a CF corrector study

Galapagos doses first patient with novel CF corrector GLPG2222

Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of the first patient with cystic fibrosis (CF) Class III (F508del and a gating mutation like G551D) with novel CF corrector GLPG2222 as an add-on to Kalydeco®[1] in a Phase 2a study. Galapagos further announced the opening of an Investigational New Drug (IND) file with the US Food & Drug Administration for GLPG2222, triggering a $10 million milestone payment.
Continue reading Phase 2a CF corrector study